Yeah I keep an eye on this one daily. Watching for some option activity. Remember, their stuff is a few years away. At least 2023 as I recall.
CRSP is thinking about doing the dreaded death cross here at $127... But... The last time all 3 moving averages converged it took off. You need to check up on them Stoney. $127 might be a buy. They had that pin-action run last month on that other company's news.... what's in the works? And the other one.... $EDIT
Hey Van widest Bid/Ask I have ever seen-WTF- Why does this name have so many symbols? SEZNL SEZZLE INC CHESS DEP INT $6.150.000(0.00%)Bid x Size$4.80x 200Ask x Size$11.10x 100
5 shares traded. Could I not set this off with 1 1000 share lot? - These guys recently did a deal with Barstool... they can't be that small..
Van- I think the ugly duckling rout is the way to go. CRSP I think has Sickle Cell next up. uniQure filing delay could yield better label for EtranaDez, says Chardan 06/23 QURE After uniQure hosted a virtual R&D Day, announced a definitive agreement to acquire private Corlieve Therapeutics and reported new 52-week data for AAV5-based gene therapy EtranaDez in hemophilia B while announcing a BLA filing is delayed one quarter to the first quarter of 2022, Chardan analyst Gbola Amusa said the push out could result in a better label with enhanced durability statements. The analyst, who also noted that the 52-week data from the phase 3 HOPE-B trial show sustained increases in factor IX activity, has a Buy rating and $100 price target on uniQure shares. Yes $100 target on a $27 stk.......
Van life moves in mysterious ways look! uniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress uniQure Inc. July 2, 2021 In this article: Explore the topics mentioned in this article LEXINGTON, Mass. and AMSTERDAM, The Netherlands, July 02, 2021 (GLOBE NEWSWIRE) --uniQure N.V.(NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that eight data presentations, of which three are oral presentations, will be delivered at the International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress being held July 17-21, 2021. ThaT's THIS WEEKEND!!!!!!! LET'S DO THIS!
I like it. I was doing some dd on that analyst after I read your post. Pretty impressive chap. Dr. Amusa has roughly 20 years of experience in healthcare finance. He joined Chardan in 2014 to focus on identifying companies that will generate exceptionally high long-term investment returns by creating and sharing in real value for society. This goal has been achieved throughout his tenure in Chardan research, including in 2019 when he finished 2nd out of more than 6,000 Wall Street analysts in a TipRanks study on stock picking. Prior to joining Chardan, Dr. Amusa was Managing Director, Head of European Pharma Research, and Global Pharma & Biotech Coordinator at UBS, where he oversaw 25 analysts, and ultimately finished as the #1 ranked European pharma analyst in the Institutional Investor (II) Survey. Prior to UBS, Dr. Amusa was a Senior Research Analyst and Head of European Pharma research at Sanford Bernstein. He started his career in finance at Goldman Sachs as an Associate in the Healthcare Investment Banking Group, where he worked on large transactions including the Amgen/Immunex merger. Additionally, Dr. Amusa was previously a Healthcare Finance & Strategy Consultant working with governments, companies, leading foundations and think tanks. His views on healthcare have been cited by socially responsible investing (SRI), ESG and sustainability organizations like FSG/Shared Value Initiative, GMI Ratings and the ATM Index. Dr. Amusa earned his BSE with honors in biomedical engineering from Duke University, an MD from Washington University Medical School, and his MBA with high honors from the University of Chicago, Booth School of Business.